To evaluate the cost effectiveness of Public-Private Partnerships (PPPs) for the development of drugs and diagnostics for leishmaniasis and other NTDs from the public health perspective and the market/business impact
The results of this study will provide relevant information to public and private institutions working on the development of drugs and diagnostics for NTDs on the impact of the model applied in the last 10 years.
Background: The unavailability of medicines and diagnostic tools for NTDs results in enormous human and economic costs and is largely due to the fact that there is little economic incentive for the for-profit pharmaceutical companies to develop medicines and diagnostic tools for people in poor countries. In recent years PPP have contributed to fill this gap. From the public health system perspective, it is needed to evaluate if and how the PPP model is a cost-effective strategy to reduce the burden associated with NTDs14. From the private perspective, the various market and business impacts in participating into these new business models should be identified and quantified. PPPs can be considered as a new pathway to reinforce the position of for-profit companies into new commercial markets in emerging economies or a powerful indirect commercial strategy by implementing corporate social responsibility policy.
Methodology: Cost-effectiveness analysis of PPPs will be performed against contexts in which no-PPP is created and either drugs or diagnostic tools are developed and produced according to standard market procedures. A case-control study will be undertaken to evaluate the impact of PPPs on commercial and market selected indicators. Such indicators will be retrospectively analysed before and after the development and the supply of new drugs/diagnostics for leishmaniasis and other NTDs.